Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2026

Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India.

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDebdulal ChakrabortyTSTushar Kanti SinhaSBSubhendu Boral

Discussion

Loading...

Member takes

Overview

Narrative review evaluates clinical efficacy, safety, and cost-effectiveness of biosimilar anti-VEGF agents in improving retinal care in India, suggesting strong implications for accessibility.

Key Points

  • The aim is to assess the clinical outcomes, safety, and cost-effectiveness of biosimilar anti-VEGF agents in the management of retinal vascular diseases in India.
  • Conducted a comprehensive literature search in PubMed, MEDLINE, EMBASE, and Scopus.
  • Included randomized trials, phase 3 studies, and real-world cohorts from India.
  • Focused on clinical efficacy, safety, and cost-effectiveness of biosimilar ranibizumab.
  • Phase 3 trials demonstrate equivalence of biosimilars to the reference molecule in visual outcomes.
  • Large real-world datasets confirm low immunogenicity and comparable safety profiles.
  • Reduction in treatment costs has improved treatment initiation and adherence.

Cite This Study

Chakraborty et al. (2026) studied this question.

synapsesocial.com/papers/69f4435b967e944ac55669efhttps://doi.org/10.4103/ijo.ijo_3222_25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biosimilars in Retinal Disorders: Cost Revolution or Clinical Trade-off in the Indian Scenario?2025
  2. 2Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects2026
  3. 3Peep into anti-vascular endothelial growth factor2026
  4. 4EFFECTIVENESS AND SAFETY OF BIOSIMILAR ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL DISEASES2026
  5. 5Efficacy and safety of ranibizumab biosimilar for retinal diseases: A systematic review and meta-analysis2026